RxDoctor Payments Data

Scott Eggener

Urology · Chicago, ILNPI 1548440027

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Johnson & Johnson at 44.0% of the total. Reporting peaked in 2019 at $34,861 and has fallen 99.1% since, to $328 in 2025. Among urology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$64,248in general payments, 2019–2025

Across 56 payments — averaging $1147.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$28K
  • Janssen Scientific Affairs, LLC$12K
  • Insightec,inc$9K
  • AstraZeneca$5K
  • Progenics Pharmaceuticals, Inc.$4K
  • Janssen Global Services, LLC$2K
  • plus $2K from 5 others
$24,119in research payments, 2019–2025

Across 4 payments — averaging $6029.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Progenics Pharmaceuticals, Inc.$21K
  • Astellas Pharma Global Development$3K

What the payments were for

  • Consulting fees$26,90342%
  • Speaking & faculty fees$29,45046%
  • Travel & lodging$6,14510%
  • Food & beverage$1,7513%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,248 in reported general payments places this provider in the 95th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$159,603
Medicare patients
495
Services billed
797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl15$324

Paid to pharmacies, not to this prescriber.

Other urology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →